Pfizer, Inc. · NYSE:PFE
Pfizer — Goldman Sachs Key Debates In Biosimilars Conference 2015
10 slides from Pfizer's conference presentation, Apr 2, 2015
Slide 1: Goldman Sachs Key Debates In Biosimilars Conference
Goldman Sachs Key Debates In Biosimilars Conference Diem Nguyen Regional President North America, Global Established Pharmaceuticals April 2, 2015 1
Slide 2: Forward Looking Statements
Forward Looking Statements Our discussions during this presentation will include forward-looking statements about, among other things, Pfizer’s biosimilars pipeline, including its potential benefits, anticipated industry growth rates and Pfizer’s planned acquisition of Hospira, including its potenti
Slide 3: Biosimilars: Attractive Growth Opportunity
Biosimilars: Attractive Growth Opportunity >$100B of biologics lose patent protection in next 5-10 years Biosimilars are a potential lever to provide savings and efficiencies to healthcare systems as well as to expand access in many markets to these important medicines Development, regulatory,
Slide 4: What Biosimilars Are Not: Generics
What Biosimilars Are Not: Generics Small molecule • Proof of quality (identical chemical structure) Generics • Pharmacokinetic bioequivalence • Relies on existing clinical data from reference product’s label Biopharmaceutical Biosimilars • Proof of quality and similarity • Pharmacokinetic bioequival
Slide 5: The Potential of Biosimilars
The Potential of Biosimilars “Because of their biologic complexity, mass producing these medicines calls for a new approach to management and continuous improvement, which requires the highest levels of attention to quality, precision and consistency.” – David Niles, president, SSA & Company and Boa
Slide 6: Pfizer Point Of View: Patient Is At The Center
Pfizer Point Of View: Patient Is At The Center. Policy Should Be Established Based On Science And Physician Care Approval and extrapolation should be based on the totality of data and the demonstration of similarity in quality, clinical and non-clinical parameters Regulatory Framework For biosimilar
Slide 7: Pfizer Well Positioned to Be a Leader in Biosimilars
Pfizer Well Positioned to Be a Leader in Biosimilars • Robust efficacy / safety • Device options Physician / Clinical Data • Physician education • Multiple disease states Package Patient (if relevant) Offerings • Patient support services • Biologics manufacturing, supply • Physicians and patients Bi
Slide 8: Pfizer Biosimilars Strategy: Investing In Hard-To-Make Monoclonal Antibodies
Pfizer Biosimilars Strategy: Investing In Hard-To-Make Monoclonal Antibodies Potential Biosimilars in Development Remicade® Herceptin® Avastin® Humira® (infliximab) (trastuzumab) (bevacizumab) (adalimumab) Oncology Inflammation Herceptin® and Avastin® are registered U.S. trademarks of Genentech, Inc
Slide 9: Key Takeaways
Key Takeaways Biosimilars present a strong growth opportunity, with an expected market size of approximately $20Bn of gross sales by 2020* The introduction of high quality, safe, and effective biosimilars has the potential to provide savings and efficiencies to healthcare systems and the potenti
Slide 10: Goldman Sachs Key Debates In Biosimilars Conference
Goldman Sachs Key Debates In Biosimilars Conference Q&A Session April 2, 2015 10
Pfizer — Goldman Sachs Key Debates In Biosimilars Conference 2015 on 6ix